Ceftazidime Injection shortage
To Be DiscontinuedCeftazidime Injection is currently listed as To Be Discontinued in the FDA Drug Shortage Database. Reported reason: Not specified.
Therapeutic category
Dosage form
Injection
Routes
INTRAVENOUS
Last updated
11/14/2025
Strength variants
- Not specified
Need sourcing help for Ceftazidime Injection?
Get connected with licensed distributors and 503B compounders that can fulfill orders during active shortages. Verified suppliers, no spam.
Connect with a sourcing partnerManufacturers reporting shortage
- Hospira, Inc., a Pfizer Company844-646-4398To Be Discontinued
- Hospira, Inc., a Pfizer Company844-646-4398To Be Discontinued
Reason for shortage
ad slot 300x250
Related shortages in Anti-Infective
Rifampin Capsule
- Category
- Anti-Infective
- Reason
- Not specified
- Updated
- 04/08/2026
Rifampin Capsule
- Category
- Anti-Infective
- Reason
- Discontinuation of the manufacture of the drug
- Updated
- 04/08/2026
Rifampin Capsule
- Category
- Anti-Infective
- Reason
- Discontinuation of the manufacture of the drug
- Updated
- 04/08/2026
Rifampin Capsule
- Category
- Anti-Infective
- Reason
- Discontinuation of the manufacture of the drug
- Updated
- 04/08/2026
Rifampin Capsule
- Category
- Anti-Infective
- Reason
- Not specified
- Updated
- 04/08/2026
Rifampin Capsule
- Category
- Anti-Infective
- Reason
- Discontinuation of the manufacture of the drug
- Updated
- 04/08/2026
This information is not medical advice. Consult your pharmacist. Data is sourced from the FDA Drug Shortage Database and may not reflect real-time inventory at your facility. ShortageWatch is independent and not affiliated with the FDA.